Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Kala Pharmaceuticals Inc (NQ: KALA )

7.440 USD +0.080 (+1.09%)
Streaming Delayed Price Updated: 12:20 PM EST, Mar 2, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 716,487
Open 7.360
Bid (Size) 7.440 (3)
Ask (Size) 7.450 (7)
Prev. Close 7.360
Today's Range 7.270 - 7.540
52wk Range 5.040 - 14.68
Shares Outstanding 24,562,400
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that... 
From Business Wire News Releases
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported... 
From Business Wire News Releases

Performance

YTD
+8.45%
+8.45%
1 Month
-2.87%
-2.87%
3 Month
-0.27%
-0.27%
6 Month
-16.40%
-16.40%
1 Year
+24.41%
+24.41%

More News

Read More
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
From Business Wire News Releases
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Business Wire News Releases
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts
From Business Wire News Releases
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Business Wire News Releases
Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline
From Business Wire News Releases
Analysts Expect IEIH Will Reach $39
Tags ETFs
From ETF Channel
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January
From Business Wire News Releases
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Business Wire News Releases
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.